trial · primary record
Asciminib
Malignant Solid Tumors
| Phase | Phase 2 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 40 |
| Primary completion | 2028-12-31 |
| Primary endpoint | Major molecular response (MMR) rate by 12 months |
| Registry ID | NCT06629584 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-11-02T15:46:14.558Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT06629584
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.
Same entity, elsewhere in the suite
- Asciminib · compound